Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Intervention not reported

FEV1 · children and adults with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1146 participants
Low

Intervention not reported

Time to next exacerbation · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Participant satisfaction or preference · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Treatment time · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Quality of life · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Serum deposition Cmax · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Time to next exacerbation · children and adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Adverse events · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

FEV1 · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Time to next exacerbation · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs AAD

Participant satisfaction or preference · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Treatment time (minutes) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Quality of life CFQ‐R scores (treatment burden domain and respiratory domain) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Serum deposition Cmax · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

FEV1 % predicted · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 85 participants
Low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Participant satisfaction or preference · children and adults with cystic fibrosis

It is very uncertain whether the intervention changes participant satisfaction or preference (very low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 2.33 [0.83, 6.54]
101 participants
Very low

Summary of findings ‐ nebulisers for delivering dornase alfa conventional system vs VMT

Participant satisfaction or preference · adults and children with cystic fibrosis

Summary of findings ‐ nebulisers for delivering dornase alfa:… may leads to lower participant satisfaction or preference: compared with VMT (low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.48 [0.31, 0.76]
1 study · 68 participants
Low

Intervention not reported

Treatment time · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found